Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)
- Registration Number
- NCT00903721
- Lead Sponsor
- Organon and Co
- Brief Summary
The investigation will be conducted to define safety and efficacy under the conditions of post-marketing use of this drug in subjects with allergic rhinitis.
Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3806
Inclusion Criteria
- Patients who are treated with Nasonex for perennial or seasonal allergic rhinitis.
Exclusion Criteria
- Patients with an infection for which there is no effective antimicrobial drug or systemic fungal infection [symptoms may exacerbate]
- Patients with a history of hypersensitivity to any ingredient of this drug
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 2 mometasone furoate Patients with seasonal allergic rhinitis (including patients who also have perennial allergic rhinitis) 1 mometasone furoate Patients with perennial allergic rhinitis
- Primary Outcome Measures
Name Time Method Estimate the incidence of Adverse Drug Reactions (ADRs) After 6 months of observation
- Secondary Outcome Measures
Name Time Method